DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta type 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta type 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta type 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
peptidylprolyl isomerase B (PPIB) — PPIB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet akgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8K0M · 3.17 Å · ligand 2-OXOGLUTARIC ACID (AKG). Experimental structure, not a prediction.
What the evidence adds up to
No abstract in this set reports a drug trial for osteogenesis imperfecta type 9. A 1981 review of systemic treatment for osteogenesis imperfecta in general states that seventy percent of published articles on medical treatment claimed beneficial results for twenty different agents, yet no form of treatment had been accepted as effective. The review advises practitioners to maintain a high degree of skepticism toward positive results regardless of source, and concludes that at that time no agent was available of any value to the practitioner.
A 2025 case report describes a newborn with osteogenesis imperfecta type XV, a rare recessive form caused by a WNT1 gene mutation. The report mentions bisphosphonate therapy and the prospects for targeted drug use as therapeutic strategies discussed in the context of that case. No data on response, survival, or sample size are given. A 2013 review notes that mutations in various noncollagenous genes have been discovered to cause some recessive forms of osteogenesis imperfecta, but does not report any treatment results for type 9.
A 2021 case report on implant-prosthetic restoration in a patient with type I osteogenesis imperfecta warns that for patients receiving additional antiresorptive therapy, cautious approaches should be chosen and the risk of drug-associated osteonecrosis considered. No abstract provides any evidence for drug treatment of osteogenesis imperfecta type 9 specifically. What is missing is any clinical trial data, any patient stratification by genetic subtype, and any funding for a trial that would test a drug in type 9.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Orthopaedics and Related Research · 1981 · 40 citations
Systemic Treatment of Osteogenesis Imperfecta
AbstractSeventy percent of published articles on the medical treatment of osteogenesis imperfecta have claimed beneficial results for 20 different agents. This observation conflicts with current practice since no form of treatment has been accepted as effective in dealing with the disease. A few medications or combinations of medications hold some promise, but adequate documentation must be availble before they can be accurately assessed. It is essential that the practitioner maintain a high degree of skepticism toward positive results of treatment regardless of the source. At the present time, no agent is available which will be of any value to the practitioner who has a patient with osteogenesis imperfecta.
International Journal of Environmental Research and Public Health · 2021 · 3 citations · open access
Implant-Prosthetic Restoration of a Patient with Osteogenesis Imperfecta: A Case Report
AbstractOsteogenesis imperfecta describes a group of genetic disorders that result from a defect in collagen type I and range in severity from a subtle increase in fracture frequency to death in the perinatal period. Osteogenesis imperfecta is mostly caused by mutations in the COL1A1 (17q21.33) and COL1A2 (7q21.3) genes. There have only been a few case reports of implant-prosthetic treatment for patients with osteogenesis imperfecta. These reports indicated that implants and augmentation procedures can be implemented in such patients. However, for patients receiving additional antiresorptive therapy, cautious approaches should be chosen and the risk of drug-associated osteonecrosis should be considered. The aim of this article is to report on the implant-prosthetic treatment of a patient with type I osteogenesis imperfecta.
Traumatology and Orthopаedics of Kazakhstan · 2025 · 0 citations · open access
Osteogenesis imperfecta type XV: A clinical case
AbstractThe article presents a clinical case of a rare form of osteogenesis imperfecta (type XV) identified in a newborn girl. The key clinical manifestations, genetic aspects of the disease and approaches to diagnostics are described. The results of laboratory and instrumental studies confirming the diagnosis are presented. Therapeutic strategies, including bisphosphonate therapy and the prospects for targeted drug use, are discussed. The work emphasizes the importance of early diagnosis and a multidisciplinary approach to optimize the treatment of patients with this condition.Keywords: osteogenesis imperfecta type XV, rare genetic disorders, WNT1 gene mutation, bisphosphonate therapy, targeted therapy.
AbstractThis article discusses the pathophysiology of osteogenesis imperfecta (OI), in particular in relation to some rare, recessive forms of the condition. Although historically considered a collagen-related condition, predominantly due to mutations in genes that encode the alpha chains of collagen type I, mutations in various noncollagenous genes have also more recently been discovered to cause some forms of OI.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
